Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**18F-THK5105** is a radiolabeled small molecule diagnostic agent developed for positron emission tomography (PET) imaging of tau protein aggregates in the brain. It is an arylquinoline derivative labeled with fluorine-18 and acts as a selective tracer for neurofibrillary tangles composed of tau protein, which are characteristic of Alzheimer's disease and other tauopathies. The compound demonstrates high binding affinity to tau aggregates in vitro and in vivo, with rapid brain uptake and favorable pharmacokinetics compared to earlier tracers. Its primary use is as a PET imaging probe to visualize the distribution and burden of pathological tau in patients suspected of having Alzheimer's disease or related disorders[1][2][3][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 18F-THK5105.